Bulletin
Investor Alert

London Markets Open in:

Adamis Pharmaceuticals Corp.

NAS: ADMP

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 18, 2022, 7:51 p.m.

/zigman2/quotes/205166351/composite

$

0.44

Change

+0.02 +4.03%

Volume

Volume 15,017

Quotes are delayed by 20 min

/zigman2/quotes/205166351/composite

Previous close

$ 0.43

$ 0.42

Change

-0.0025 -0.59%

Day low

Day high

$0.42

$0.44

Open

52 week low

52 week high

$0.31

$1.48

Open

Company Description

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and...

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

Valuation

Price to Sales Ratio

39.49

Price to Book Ratio

3.50

Enterprise Value to EBITDA

-1.35

Enterprise Value to Sales

18.75

Efficiency

Total Asset Turnover

0.06

Liquidity

Current Ratio

3.14

Quick Ratio

3.10

Cash Ratio

2.07

Profitability

Gross Margin

-211.14

Operating Margin

-1,451.97

Pretax Margin

-1,566.53

Net Margin

-1,566.56

Return on Assets

-99.45

Return on Equity

-235.53

Return on Total Capital

-173.67

Capital Structure

Total Debt to Total Assets

1.81

Officers and Executives

Name Age Officer Since Title
Dr. Dennis J. Carlo 75 2009 President, Chief Executive Officer & Director
Mr. David C. Benedicto 59 2014 Senior Director-Accounting & Controller
Dr. Ronald B. Moss 59 2017 Chief Medical Officer
Dr. Thomas H. Moll 54 2009 Vice President-Research
Mr. David J. Marguglio 48 2006 Director & Senior VP-Corporate Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/18/2022 Dennis J. Carlo
President & CEO; Director
10,490   Disposition at $0.6 per share. 6,294
03/18/2022 David J. Marguglio
SVP and Chief Business Officer; Director
11,859   Disposition at $0.6 per share. 7,115
03/18/2022 Ronald B. Moss
Chief Medical Officer
8,199   Disposition at $0.6 per share. 4,919
03/18/2022 David C. Benedicto
Chief Financial Officer
3,603   Disposition at $0.61 per share. 2,197
12/09/2021 David J. Marguglio
SVP and Chief Business Officer; Director
13,000   Gift at $0 per share. 0
12/01/2021 Dennis J. Carlo
President & CEO; Director
47,870   Disposition at $0.78 per share. 37,338
12/01/2021 David J. Marguglio
SVP and Chief Business Officer; Director
50,757   Disposition at $0.78 per share. 39,590
12/01/2021 Ronald B. Moss
Chief Medical Officer
35,553   Disposition at $0.78 per share. 27,731
12/01/2021 David C. Benedicto
Chief Financial Officer
13,554   Disposition at $0.78 per share. 10,572
02/21/2021 Dennis J. Carlo
President & CEO; Director
27,822   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2021 Robert O. Hopkins
Chief Financial Officer
22,258   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2021 David J. Marguglio
SVP and Chief Business Officer; Director
22,258   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2021 Ronald B. Moss
Chief Medical Officer
13,911   Derivative/Non-derivative trans. at $0 per share. 0
11/20/2020 Robert O. Hopkins
Chief Financial Officer
35,000   Disposition at $0.41 per share. 14,350
11/20/2020 David J. Marguglio
SVP and Chief Business Officer; Director
35,000   Disposition at $0.4 per share. 14,000
11/18/2020 Dennis J. Carlo
President & CEO; Director
10,665   Disposition at $0.41 per share. 4,372
11/18/2020 Robert O. Hopkins
Chief Financial Officer
7,229   Disposition at $0.41 per share. 2,963
11/18/2020 David J. Marguglio
SVP and Chief Business Officer; Director
8,532   Disposition at $0.41 per share. 3,498
11/18/2020 Ronald B. Moss
Chief Medical Officer
8,532   Disposition at $0.41 per share. 3,498
11/18/2020 Karen K. Daniels
VP of Operations
5,333   Disposition at $0.41 per share. 2,186
09/29/2020 Robert O. Hopkins
Chief Financial Officer
20,000   Disposition at $0.8 per share. 16,000
09/29/2020 David J. Marguglio
SVP and Chief Business Officer; Director
20,000   Disposition at $0.8 per share. 16,000
08/18/2020 Dennis J. Carlo
President & CEO; Director
10,929   Disposition at $0.87 per share. 9,508
08/18/2020 Robert O. Hopkins
Chief Financial Officer
7,418   Disposition at $0.87 per share. 6,453
08/18/2020 David J. Marguglio
SVP and Chief Business Officer; Director
8,749   Disposition at $0.87 per share. 7,611
08/18/2020 Ronald B. Moss
Chief Medical Officer
8,749   Disposition at $0.87 per share. 7,611
08/18/2020 Karen K. Daniels
VP of Operations
5,480   Disposition at $0.87 per share. 4,767
05/19/2020 Karen K. Daniels
VP of Operations
4,855   Disposition at $0.56 per share. 2,718
05/18/2020 Dennis J. Carlo
President & CEO; Director
9,913   Disposition at $0.56 per share. 5,551
05/18/2020 Robert O. Hopkins
Chief Financial Officer
6,532   Disposition at $0.56 per share. 3,657
05/18/2020 David J. Marguglio
SVP and Chief Business Officer; Director
7,734   Disposition at $0.56 per share. 4,331
05/18/2020 Ronald B. Moss
Chief Medical Officer
7,736   Disposition at $0.56 per share. 4,332
/news/latest/company/us/admp

MarketWatch News on ADMP

  1. Adamis Pharmaceuticals downgraded to hold from buy at Maxim Group

    12:30 p.m. Nov. 16, 2020

    - Tomi Kilgore

  2. Adamis Pharmaceuticals downgraded to neutral at Dawson James

    9:14 a.m. Feb. 27, 2020

    - Tomi Kilgore

  3. Adamis Pharma downgraded to market perform vs. outperform at Raymond James

    9:47 a.m. Nov. 26, 2019

    - Ciara Linnane

  4. Adamis shares tumble after letter from FDA

    4:16 p.m. Nov. 25, 2019

    - Jaimy Lee

  5. Adamis Pharmaceuticals downgraded to sell from neutral at B. Riley FBR

    7:06 a.m. July 16, 2019

    - Tomi Kilgore

  6. Adamis Pharmaceuticals stock price target cut to $6 from $10 at Maxim Group

    7:52 a.m. July 9, 2019

    - Tomi Kilgore

  7. Adamis Pharmaceuticals started at buy with $5 stock price target at Dawson James

    7:46 a.m. July 2, 2019

    - Tomi Kilgore

  8. Adamis Pharmaceuticals stock price target cut to $6.70 from $8.50 at Raymond James

    7:40 a.m. March 19, 2019

    - Tomi Kilgore

  9. Adamis stock surges on release of EpiPen alternative

    5:48 p.m. Jan. 16, 2019

    - Wallace Witkowski

  10. Makers of EpiPen and rival products have shares drop after Teva appproval

    1:03 p.m. Aug. 16, 2018

    - Emma Court

  11. Teva stock surges 7% after FDA approves first rival generic EpiPen

    1:02 p.m. Aug. 16, 2018

    - Emma Court

  12. Novartis buys U.S. rights to EpiPen rival

    6:09 p.m. July 2, 2018

    - MarketWatch.com

  13. Stocks close higher as technology shares rally

    4:42 p.m. July 2, 2018

    - Sue Chang

  14. Loading more headlines...
/news/nonmarketwatch/company/us/admp

Other News on ADMP

  1. Notable earnings after Monday's close

    5:35 p.m. May 15, 2022

    - Seeking Alpha

  2. 10-K: ADAMIS PHARMACEUTICALS CORP

    5:05 p.m. March 31, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  3. Warning: ADMP is at high risk of performing badly

    5:20 a.m. Dec. 8, 2021

    - Seeking Alpha

  4. Adamis Pharmaceuticals: It's Now Or Never

    12:18 a.m. Dec. 2, 2021

    - Seeking Alpha

  5. Warning: ADMP is at high risk of performing badly

    5:43 a.m. Nov. 24, 2021

    - Seeking Alpha

  6. 10-Q: ADAMIS PHARMACEUTICALS CORP

    6:17 p.m. Nov. 22, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  7. Loading more headlines...

At a Glance

Adamis Pharmaceuticals Corp.

11682 El Camino Real

Suite 300

San Diego, California 92130

Phone

1 8589972400

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$2.21M

Net Income

$-34.60M

Employees

15.00

/news/pressrelease/company/us/admp

Press Releases on ADMP

  1. Loading more headlines...
Link to MarketWatch's Slice.